OKUR (OnKure Therapeutics) Other Current Liabilities: $1.12 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OKUR OnKure Therapeutics Inc OKUR
14 GF Score
Price $4.12
! 1 Warning Sign
View Full Analysis

What is OnKure Therapeutics Other Current Liabilities?

OnKure Therapeutics OKUR -1.90% 14 Other Current Liabilities is $1.12 Mil as of Mar. 2026. GuruFocus rates OKUR with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

OnKure Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was $1.12 Mil.

OnKure Therapeutics's quarterly other current liabilities declined from Sep. 2025 ($2.98 Mil) to Dec. 2025 ($2.69 Mil) and declined from Dec. 2025 ($2.69 Mil) to Mar. 2026 ($1.12 Mil).

OnKure Therapeutics's annual other current liabilities increased from Dec. 2023 ($1.66 Mil) to Dec. 2024 ($3.17 Mil) but then declined from Dec. 2024 ($3.17 Mil) to Dec. 2025 ($2.69 Mil).

OnKure Therapeutics Other Current Liabilities Related Terms

OnKure Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for OnKure Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OnKure Therapeutics Other Current Liabilities Chart

OnKure Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
1.46 1.66 3.17 2.69

OnKure Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.38 2.10 2.98 2.69 1.12
OKUR
14GF Score
OnKure Therapeutics Inc OKUR
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OnKure Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $1.12 Mil mean?
OnKure Therapeutics (OKUR) has a Other Current Liabilities of $1.12 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on OnKure Therapeutics.
Is OnKure Therapeutics' Other Current Liabilities too high?
OnKure Therapeutics' current Other Current Liabilities is $1.12 Mil. Overall, OnKure Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does OnKure Therapeutics' Other Current Liabilities compare to ANTX and PLX?
OnKure Therapeutics' Other Current Liabilities of $1.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on OnKure Therapeutics. OnKure Therapeutics's current Other Current Liabilities is $1.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OnKure Therapeutics stock overvalued right now?
OnKure Therapeutics (OKUR) has a current Other Current Liabilities of $1.12 Mil. The current Other Current Liabilities is $1.12 Mil. OnKure Therapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For OnKure Therapeutics (OKUR), the current Other Current Liabilities is $1.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OnKure Therapeutics Business Description

Address 6707 Winchester Circle, Suite 400, Boulder, CO, USA, 80301
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3K?. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
14GF Score

Get the complete analysis for OKUR

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.12
Price